Eli Lilly (LLY) EBIT Margin (2009 - 2026)
Eli Lilly posted quarterly EBIT Margin of 47.98% for Q1 2026, up 660.0% year-on-year from 6.31% in Q1 2025, and up 3.96% on a QoQ basis from 46.15% in Q4 2025.
Eli Lilly (LLY) has 18 years of EBIT Margin data on file, last reported at 47.98% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin rose 660.0% year-over-year to 47.98%; the trailing twelve-month figure through Mar 2026 stood at 46.29% (up 787.0% YoY), and the FY2025 full-year result was 44.82%, up 890.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 47.98%, up from 46.15% in the prior quarter.
- Across five years, EBIT Margin topped out at 47.98% in Q1 2026 and bottomed at 22.97% in Q1 2023.
- The 5-year median for EBIT Margin is 34.23% (2024), against an average of 35.15%.
- The widest annual swing landed in 2023, when EBIT Margin tumbled 993 bps; it then soared 1150 bps in 2025.
- A 5-year view of EBIT Margin shows it stood at 28.44% in 2022, then advanced by 13 bps to 32.18% in 2023, then advanced by 23 bps to 39.44% in 2024, then grew by 17 bps to 46.15% in 2025, then gained by 4 bps to 47.98% in 2026.
- The last three EBIT Margin figures came in at 47.98% (Q1 2026), 46.15% (Q4 2025), and 45.57% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 47.98% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 26.44% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 26.60% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -286.83% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -1.58% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.98% |
| Dec 31, 2025 | 46.15% |
| Sep 30, 2025 | 45.57% |
| Jun 30, 2025 | 45.13% |
| Mar 31, 2025 | 41.38% |
| Dec 31, 2024 | 39.44% |
| Sep 30, 2024 | 38.05% |
| Jun 30, 2024 | 34.23% |
| Mar 31, 2024 | 29.88% |
| Dec 31, 2023 | 32.18% |
| Sep 30, 2023 | 36.06% |
| Jun 30, 2023 | 26.74% |
| Mar 31, 2023 | 22.97% |
| Dec 31, 2022 | 28.44% |
| Sep 30, 2022 | 25.05% |
| Jun 30, 2022 | 25.44% |
| Mar 31, 2022 | 32.91% |
| Dec 31, 2021 | 29.44% |
| Sep 30, 2021 | 30.40% |
| Jun 30, 2021 | 21.46% |
| Mar 31, 2021 | 21.56% |
| Dec 31, 2020 | 33.17% |
| Sep 30, 2020 | 22.27% |
| Jun 30, 2020 | 26.16% |
| Mar 31, 2020 | 28.04% |
| Dec 31, 2019 | 25.38% |
| Sep 30, 2019 | 27.54% |
| Jun 30, 2019 | 27.02% |
| Mar 31, 2019 | 23.68% |
| Dec 31, 2018 | 25.23% |
| Sep 30, 2018 | 26.68% |
| Jun 30, 2018 | 28.54% |
| Mar 31, 2018 | 27.26% |
| Dec 31, 2017 | 19.89% |
| Sep 30, 2017 | 20.38% |
| Jun 30, 2017 | 21.46% |
| Mar 31, 2017 | 20.17% |
| Dec 31, 2016 | 18.29% |
| Sep 30, 2016 | 19.05% |
| Jun 30, 2016 | 18.16% |
| Mar 31, 2016 | 17.41% |
| Dec 31, 2015 | 13.84% |
| Sep 30, 2015 | 20.24% |
| Jun 30, 2015 | 19.19% |
| Mar 31, 2015 | 19.14% |
| Dec 31, 2014 | 17.23% |
| Sep 30, 2014 | 14.22% |
| Jun 30, 2014 | 17.96% |
| Mar 31, 2014 | 18.50% |
| Dec 31, 2013 | 17.10% |
| Sep 30, 2013 | 26.76% |
| Jun 30, 2013 | 26.42% |
| Mar 31, 2013 | 25.77% |
| Dec 31, 2012 | 21.29% |
| Sep 30, 2012 | 20.93% |
| Jun 30, 2012 | 21.47% |
| Mar 31, 2012 | 25.08% |
| Dec 31, 2011 | 17.67% |
| Sep 30, 2011 | 25.80% |
| Jun 30, 2011 | 25.41% |
| Mar 31, 2011 | 28.65% |
| Dec 31, 2010 | 23.42% |
| Sep 30, 2010 | 27.79% |
| Jun 30, 2010 | 28.55% |
| Mar 31, 2010 | 30.69% |
| Dec 31, 2009 | 21.82% |
| Sep 30, 2009 | 17.82% |
| Jun 30, 2009 | 28.19% |
| Mar 31, 2009 | 34.76% |